Medigen Biotechnology Stock Cash Flow From Operations
| 3176 Stock | TWD 34.75 0.45 1.28% |
Medigen Biotechnology fundamentals help investors to digest information that contributes to Medigen Biotechnology's financial success or failures. It also enables traders to predict the movement of Medigen Stock. The fundamental analysis module provides a way to measure Medigen Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Medigen Biotechnology stock.
Medigen |
Medigen Biotechnology Company Cash Flow From Operations Analysis
Medigen Biotechnology's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Medigen Biotechnology Cash Flow From Operations | 518.12 M |
Most of Medigen Biotechnology's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medigen Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Medigen Biotechnology has 518.12 M in Cash Flow From Operations. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The cash flow from operations for all Taiwan stocks is notably lower than that of the firm.
Medigen Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medigen Biotechnology's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Medigen Biotechnology could also be used in its relative valuation, which is a method of valuing Medigen Biotechnology by comparing valuation metrics of similar companies.Medigen Biotechnology is currently under evaluation in cash flow from operations category among its peers.
Medigen Fundamentals
| Return On Equity | -0.0022 | |||
| Return On Asset | 0.0036 | |||
| Profit Margin | (0.08) % | |||
| Operating Margin | 0.02 % | |||
| Current Valuation | 2.9 B | |||
| Shares Outstanding | 139.45 M | |||
| Shares Owned By Insiders | 25.17 % | |||
| Shares Owned By Institutions | 2.80 % | |||
| Price To Book | 2.01 X | |||
| Price To Sales | 1.66 X | |||
| Revenue | 3.92 B | |||
| Gross Profit | 2.55 B | |||
| EBITDA | 1.35 B | |||
| Net Income | (52.61 M) | |||
| Total Debt | 470.77 M | |||
| Book Value Per Share | 18.24 X | |||
| Cash Flow From Operations | 518.12 M | |||
| Earnings Per Share | (0.51) X | |||
| Number Of Employees | 18 | |||
| Beta | 0.99 | |||
| Market Capitalization | 4.42 B | |||
| Total Asset | 8.2 B | |||
| Z Score | 5.4 | |||
| Net Asset | 8.2 B |
About Medigen Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medigen Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medigen Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medigen Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Medigen Biotechnology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medigen Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medigen Biotechnology will appreciate offsetting losses from the drop in the long position's value.Moving together with Medigen Stock
Moving against Medigen Stock
The ability to find closely correlated positions to Medigen Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medigen Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medigen Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medigen Biotechnology to buy it.
The correlation of Medigen Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medigen Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medigen Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medigen Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Medigen Stock Analysis
When running Medigen Biotechnology's price analysis, check to measure Medigen Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medigen Biotechnology is operating at the current time. Most of Medigen Biotechnology's value examination focuses on studying past and present price action to predict the probability of Medigen Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medigen Biotechnology's price. Additionally, you may evaluate how the addition of Medigen Biotechnology to your portfolios can decrease your overall portfolio volatility.